{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Facon T"],"funding":["NCI NIH HHS","Janssen Research and Development"],"pagination":["942-950"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11976258"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["39(4)"],"pubmed_abstract":["In the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (<70, ≥70 to <75, ≥75, and ≥80 years). Overall, 737 transplant-ineligible patients with NDMM were randomized 1:1 to D-Rd or Rd. The primary endpoint, PFS, was improved with D-Rd versus Rd (median, 61.9 vs 34.4 months; hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.45-0.67; P < 0.0001). Median OS was not reached in the D-Rd group versus 65.5 months in the Rd group (HR, 0.66; 95% CI, 0.53-0.83"],"journal":["Leukemia"],"pubmed_title":["Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes."],"pmcid":["PMC11976258"],"funding_grant_id":["P30 CA008748","P50 CA186781"],"pubmed_authors":["Borgsten F","Moreau P","Wang G","Pei H","Raje N","Leleu X","Chari A","Basu S","Kumar SK","Facon T","Bahlis N","Krevvata M","Weisel K","Venner CP","Cook G","Carson R","Hulin C","Perrot A","Quach H","Tiab M","Usmani SZ","Jacquet C","O'Dwyer M","Frenzel L","Goldschmidt H","Plesner T","Orlowski RZ","Macro M"],"additional_accession":[]},"is_claimable":false,"name":"Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.","description":"In the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (<70, ≥70 to <75, ≥75, and ≥80 years). Overall, 737 transplant-ineligible patients with NDMM were randomized 1:1 to D-Rd or Rd. The primary endpoint, PFS, was improved with D-Rd versus Rd (median, 61.9 vs 34.4 months; hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.45-0.67; P < 0.0001). Median OS was not reached in the D-Rd group versus 65.5 months in the Rd group (HR, 0.66; 95% CI, 0.53-0.83","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-01T13:09:24.122Z","creation":"2025-07-12T03:04:26.85Z"},"accession":"S-EPMC11976258","cross_references":{"pubmed":["40016302"],"doi":["10.1038/s41375-024-02505-2"]}}